

10. (New) The method of claim 4 wherein said antagonists are selected from the group consisting of felbamate, quinoxalinediones, ACEA compounds, 1-aminocyclopropane carboxylic acid, 1,4-dihydroquinoxaline-2,3-diones, 4-hydroxy-2-quinolones, 4-amino-2-carboxytetrahydro-quinolines, trans-4-hydriopicolic acid-4-sulfate, and mixtures thereof.

11. (New) The method of claim 10 wherein said antagonist is felbamate.

12. (New) The method of claim 11 wherein said felbamate is administered in the form of oral doses of from about 100 mg/day to about 15,000 mg/day.

C¹ cont
13. (New) The method of claims 12 wherein said felbamate is administered in the form of oral doses of from about 1200 mg/day to about 7200 mg/day.

14. (New) The method of claim 5 wherein said invasive vascular procedures include coronary artery bypass graft surgery, cardiac valvular replacement, cardiac transplant, carotid endarterectomy, cerebral and peripheral aneurysmectomy, arterio-venous malformation resection, and endovascular therapy.

15. (New) The method of claim 5 wherein said antagonists are selected from the group consisting of felbamate, quinoxalinediones, ACEA compounds, 1-aminocyclopropane carboxylic acid, 1,4-dihydroquinoxaline-2,3-diones, 4-hydroxy-2-quinolones, 4-amino-2-carboxytetrahydro-quinolines, trans-4-hydriopicolic acid-4-sulfate, and mixtures thereof.

16. (New) The method of claim 15 wherein said antagonist is felbamate.

17. (New) The method of claim 16 wherein said felbamate is administered in the form of oral doses of from about 100 mg/day to about 15,000 mg/day.

18. (New) The method of claims 17 wherein said felbamate is administered in the form of oral doses of from about 1200 mg/day to about 7200 mg/day.

19 (New) The method of claim 6 wherein cerebrovascular risk factors are selected from the group consisting of hypertension, diabetes, atrial fibrillation, underlying cardiac disease, hyperlipidemia, collagen vascular disease, transient ischemic attacks, and combinations thereof.

C cont
20. (New) The method of claim 6 wherein said antagonists are selected from the group consisting of felbamate, quinoxalinediones, ACEA compounds, 1-aminocyclopropane carboxylic acid, 1,4-dihydroquinoxaline-2,3-diones, 4-hydroxy-2-quinolones, 4-amino-2-carboxytetrahydro-quinolines, trans-4-hydropipecolic acid-4-sulfate, and mixtures thereof.

21. (New) The method of claim 20 wherein said antagonist is felbamate.

22. (New) The method of claim 21 wherein said felbamate is administered in the form of oral doses of from about 100 mg/day to about 15,000 mg/day.

23. (New) The method of claim 21 wherein said felbamate is administered in the form of oral doses of from about 1200 mg/day to about 7200 mg/day.

24. (New) The method of claim 8 wherein said antagonist is administered with other medications which control and treat the underlying disease or condition.
